Molecular Perspectives on Innate Immune Homeostasis: Interlocking Roles of Natural Killer and Dendritic Cells
DOI:
https://doi.org/10.64229/hrb4yw48Keywords:
Natural killer cells, Dendritic cells, Innate immune homeostasis, NK-DC crosstalk, Immune tolerance, Tumor microenvironment, Immunotherapy, Regulatory T cellsAbstract
Innate immune homeostasis depends on the coordinated regulation of protective responses and tolerance across tissues. Although natural killer (NK) cells and dendritic cells (DCs) are traditionally viewed as cytotoxic effectors and antigen-presenting cells, respectively, accumulating evidence indicates that their reciprocal interactions actively determine the magnitude, duration, and functional direction of immune responses. This review examines the NK-DC axis as a central regulatory framework for innate immune homeostasis, integrating cellular interactions with cytokine signaling, receptor-mediated regulation, antigen presentation, and tissue-specific microenvironmental cues. We first examine NK cell development, subset specialization, activating and inhibitory receptor signaling, and effector functions, followed by analysis of DC heterogeneity, antigen processing, cross-presentation, and immunogenic versus tolerogenic programs. We then synthesize the molecular mechanisms underlying NK-DC communication, including receptor–ligand interactions, reciprocal cytokine signaling, and NK-mediated editing of DCs. Attention is given to the integration of regulatory T cells (Tregs) into this framework, in which Tregs act as downstream regulatory partners that reinforce peripheral tolerance rather than as equivalent components of the central NK-DC axis. The review further examines how checkpoint signaling, metabolic stress, hypoxia, and other features of the tissue microenvironment reshape NK-DC communication in cancer, chronic infection, and autoimmune disease. These mechanisms are considered alongside emerging therapeutic approaches, including cytokine-induced memory-like NK cells, CAR-NK therapy, immune checkpoint blockade, dendritic-cell vaccines, and tolerogenic DC-based interventions. By integrating molecular mechanisms, tissue context, disease-associated dysregulation, and therapeutic strategies, this review proposes an integrated framework for understanding how NK-DC interactions establish, maintain, and potentially restore immune homeostasis.
References
[1]Andrés CMC, Pérez de la Lastra JM, Juan CA, Plou FJ, Pérez-Lebeña E. The role of reactive species in innate immunity. Vaccines, 2022, 10(10), 1735. DOI: 10.3390/vaccines10101735
[2]Turvey SE, Broide DH. Innate immunity. Journal of Allergy and Clinical Immunology, 2010, 125(2 Suppl 2), S24-32. DOI: 10.1016/j.jaci.2009.07.016
[3]Perera Molligoda Arachchige AS. Human NK cells: From development to effector functions. Innate Immunity, 2021, 27(3), 212-229. DOI: 10.1177/17534259211001512
[4]Thomas R, Yang X. NK-DC Crosstalk in Immunity to Microbial Infection. Journal of Immunology Research, 2016, 2016, 6374379. DOI: 10.1155/2016/6374379
[5]Wang R, Lan C, Benlagha K, Camara NOS, Miller H, Kubo M, et al. The interaction of the innate immune and adaptive immune systems. MedComm, 2024, 5(10), e714. DOI: 10.1002/mco2.714
[6]Han L, Wu T, Zhang Q, Qi A, Zhou X. Immune tolerance regulation is critical to immune homeostasis. Journal of Immunology Research, 2025, 2025, 5006201. DOI: 10.1155/jimr/5006201
[7]Wicherska-Pawłowska K, Wróbel T, Rybka J. Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs are ligands as immunotherapeutic agents for hematopoietic diseases. International Journal of Molecular Sciences, 2021, 22(24), 13397. DOI: 10.3390/ijms222413397
[8]Cameron MJ, Kelvin DJ. Cytokines, chemokines, and their receptors. In: Madame Curie bioscience database. Landes Bioscience. 2013.
[9]Harvanová G, Duranková S, Bernasovská J. The role of cytokines and chemokines in the inflammatory response. Alergologia Polska-Polish Journal of Allergology, 2023, 10(3), 210-219. DOI: 10.5114/pja.2023.131708
[10]Imširović V, Wensveen FM, Polić B, Jelenčić V. Maintaining the balance: Regulation of NK cell activity. Cells, 2024, 13(17), 1464. DOI: 10.3390/cells13171464
[11]Mace EM. Human natural killer cells: Form, function, and development. The Journal of Allergy and Clinical Immunology, 2023, 151(2), 371-385. DOI: 10.1016/j.jaci.2022.09.022
[12]Le T, Reeves RK, McKinnon LR. The functional diversity of tissue-resident natural killer cells against infection. Immunology, 2022, 167(1), 28-39. DOI: 10.1111/imm.13523
[13]Bonanni V, Sciumè G, Santoni A, Bernardini G. Bone marrow NK cells: Origin, distinctive features, and requirements for tissue localization. Frontiers in Immunology, 2019, 10, 1569. DOI: 10.3389/fimmu.2019.01569
[14]Jones AB, Rocco A, Lamb LS, Friedman GK, Hjelmeland AB. Regulation of NKG2D stress ligands and its relevance in cancer progression. Cancers, 2022, 14(9), 2339. DOI: 10.3390/cancers14092339
[15]Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cell functions, signaling, molecular mechanisms, and clinical utilization. Signal Transduction And Targeted Therapy, 2024, 9(1), 302. DOI: 10.1038/s41392-024-02005-w
[16]Bozward AG, Warricker F, Oo YH, Khakoo SI. Natural killer cells and regulatory T cells cross-talk in hepatocellular carcinoma: Exploring therapeutic options for the next decade. Frontiers in Immunology, 2021, 12, 643310. DOI: 10.3389/fimmu.2021.643310
[17]Li Y, Li Z, Tang Y, Zhuang X, Feng W, Boor PPC, et al. Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. Journal for Immunotherapy of Cancer, 2024, 12(10), e009934. DOI: 10.1136/jitc-2024-009934
[18]Ramírez-Labrada A, Pesini C, Santiago L, Hidalgo S, Calvo-Pérez A, Oñate C, et al. All About (NK cell-mediated) death in two acts and an unexpected encore: Initiation, execution, and activation of adaptive immunity. Frontiers in Immunology, 2022, 13, 896228. DOI: 10.3389/fimmu.2022.896228
[19]Kumar V. Cytotoxic T cells: Kill, memorize, and mask to maintain immune homeostasis. International Journal of Molecular Sciences, 2025, 26(18), 8788. DOI: 10.3390/ijms26188788
[20]Morcillo-Martín-Romo P, Valverde-Pozo J, Ortiz-Bueno M, Arnone M, Espinar-Barranco L, Espinar-Barranco C, et al. The role of NK cells in cancer immunotherapy: Mechanisms, evasion strategies, and therapeutic advances. Biomedicines, 2025, 13(4), 857. DOI: 10.3390/biomedicines13040857
[21]Jin F, Xie L, Zhang H, Fan X, Tian J, Liu W, et al. Dendritic cells: Origin, classification, development, biological functions, and therapeutic potential. MedComm, 2025, 6(11), e70455. DOI: 10.1002/mco2.70455
[22]Vatner RE, Janssen EM. STING, DCs, and the link between innate and adaptive tumor immunity. Molecular Immunology, 2019, 110, 13-23. DOI: 10.1016/j.molimm.2017.12.001
[23]Chrisikos TT, Zhou Y, Slone N, Babcock R, Watowich SS, Li HS. Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer. Molecular Immunology, 2019, 110, 24-39. DOI: 10.1016/j.molimm.2018.01.014
[24]Hamouda AEI, Laoui D. Role of cDC2 in priming CD8+ T cells in cancer. Journal for Immunotherapy of Cancer, 2025, 13(10), e011519. DOI: 10.1136/jitc-2025-011519
[25]Ngo C, Garrec C, Tomasello E, Dalod M. The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond. Cellular & Molecular Immunology, 2024, 21(9), 1008-1035. DOI: 10.1038/s41423-024-01167-5
[26]Gerlier D, Calin-Laurens V, Bertolino P, Rabourdin-Combe C. Molecular biology of antigen presentation. In: Immune System Accessory Cells. CRC Press. 2024, 287-323.
[27]Embgenbroich M, Burgdorf S. Current concepts of antigen cross-presentation. Frontiers in Immunology, 2018, 9, 1643. DOI: 10.3389/fimmu.2018.01643
[28]Cruz FM, Chan A, Rock KL. Pathways of MHC I cross-presentation of exogenous antigens. Seminars in Immunology, 2023, 66, 101729. DOI: 10.1016/j.smim.2023.101729
[29]Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: Function, regulation, and therapeutic potential. Signal Transduction And Targeted Therapy, 2025, 10(1), 216. DOI: 10.1038/s41392-025-02264-1
[30]Duan T, Du Y, Xing C, Wang HY, Wang RF. Toll-like receptor signaling and its role in cell-mediated immunity. Frontiers in Immunology, 2022, 13, 812774. DOI: 10.3389/fimmu.2022.812774
[31]Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q, et al. Exploiting innate immunity for cancer immunotherapy. Molecular Cancer, 2023, 22(1), 187. DOI: 10.1186/s12943-023-01885-w
[32]Li X, Song S. "Dissecting the role of T cell exhaustion in cancer progression: A multifaceted approach." Frontiers in Immunology, 2025, 16, 1646292. DOI: 10.3389/fimmu.2025.1646292
[33]Polonio CM, Qualiotto AN, da Silva LT, Quintana FJ. Dendritic cells: Orchestrators of immune responsiveness and tolerance. Immunological Reviews, 2025, 336(1), e70073. DOI: 10.1111/imr.70073
[34]Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: Development, maturation, and clinical utilization. Frontiers in Immunology, 2018, 9, 1869. DOI: 10.3389/fimmu.2018.01869
[35]Jiang H, Jiang J. Balancing act: The complex role of NK cells in immune regulation. Frontiers in Immunology, 2023, 14, 1275028. DOI: 10.3389/fimmu.2023.1275028
[36]Gotthardt D, Trifinopoulos J, Sexl V, Putz EM. JAK/STAT cytokine signaling at the crossroad of NK cell development and maturation. Frontiers in Immunology, 2019, 10, 2590. DOI: 10.3389/fimmu.2019.02590
[37]Zwirner NW, Ziblat A. Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: The case of IL-27. Frontiers in Immunology, 2017, 8, 25. DOI: 10.3389/fimmu.2017.00025
[38]Vahidi S, Zabeti Touchaei A, Samadani AA. IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside. International Immunopharmacology, 2024, 133, 112156. DOI: 10.1016/j.intimp.2024.112156
[39]Harvey AG, Graves AM, Uppalapati CK, Matthews SM, Rosenberg S, Parent EG, et al. Dendritic cell-natural killer cell cross-talk modulates T cell activation in response to influenza A viral infection. Frontiers in Immunology, 2022, 13, 1006998. DOI: 10.3389/fimmu.2022.1006998
[40]Zheng J, Li X, He A, Zhang Y, Yang Y, Dang M, et al. In situ antigen-capture strategies for enhancing dendritic cell-mediated anti-tumor immunity. Journal of Controlled Release, 2025, 385, 113984. DOI: 10.1016/j.jconrel.2025.113984
[41]Zingoni A, Ardolino M, Santoni A, Cerboni C. NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: Role in the NK cell-mediated negative regulation of T cell responses. Frontiers in Immunology, 2013, 3, 408. DOI: 10.3389/fimmu.2012.00408
[42]Li R, Li H, Yang X, Hu H, Liu P, Liu H. Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis. Frontiers in Immunology, 2022, 13, 970508. DOI: 10.3389/fimmu.2022.970508
[43]Domogalla MP, Rostan PV, Raker VK, Steinbrink K. Tolerance through education: How tolerogenic dendritic cells shape immunity. Frontiers in Immunology, 2017, 8, 1764. DOI: 10.3389/fimmu.2017.01764
[44]Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine, 2016, 8(357), 357ra123. DOI: 10.1126/scitranslmed.aaf2341
[45]Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Critical Reviews in Oncogenesis, 2014, 19(1-2), 67-75. DOI: 10.1615/critrevoncog.2014010827
[46]Schiller HR, Zeigermann C, Schülke S. Role of trained immunity in DCs and macrophages in the induction of Th2 responses and allergy treatment. What do we know? Frontiers in Immunology, 2026, 17, 1748337. DOI: 10.3389/fimmu.2026.1748337
[47]Pedroza-Pacheco I, Madrigal A, Saudemont A. Interaction between natural killer cells and regulatory T cells: Perspectives for immunotherapy. Cellular & Molecular Immunology, 2013, 10(3), 222-229. DOI: 10.1038/cmi.2013.2
[48]Nie J, Zhou L, Tian W, Liu X, Yang L, Yang X, et al. Deep insight into cytokine storm: From pathogenesis to treatment. Signal Transduction And Targeted Therapy, 2025, 10(1), 112. DOI: 10.1038/s41392-025-02178-y
[49]Xiao Z, Wang R, Wang X, Yang H, Dong J, He X, et al. Impaired function of dendritic cells within the tumor microenvironment. Frontiers in Immunology, 2023, 14, 1213629. DOI: 10.3389/fimmu.2023.1213629
[50]Zhou Y, Cheng L, Liu L, Li X. NK cells are never alone: Crosstalk and communication in tumor microenvironments. Molecular Cancer, 2023, 22(1), 34. DOI: 10.1186/s12943-023-01737-7
[51]Horwitz DA, Fahmy TM, Piccirillo CA, La Cava A. Rebalancing immune homeostasis to treat autoimmune diseases. Trends in Immunology, 2019, 40(10), 888-908. DOI: 10.1016/j.it.2019.08.003
[52]Mariotti FR, Quatrini L, Munari E, Vacca P, Tumino N, Pietra G, et al. Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. British Journal of Pharmacology, 2020, 177(13), 2889-2903. DOI: 10.1111/bph.15081
[53]Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Molecular Cancer, 2024, 23(1), 108. DOI: 10.1186/s12943-024-02023-w
[54]Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Molecular Cancer, 2020, 78(6), 1019-1033. DOI: 10.1016/j.molcel.2020.05.034
[55]Lv Y, Li Z, Liu S, Zhou Z, Song J, Ba Y, et al. Metabolic checkpoints in immune cell reprogramming: Rewiring immunometabolism for cancer therapy. Molecular Cancer, 2025, 24(1), 210. DOI: 10.1186/s12943-025-02407-6
[56]Parisi L, Bassani B, Tremolati M, Gini E, Farronato G, Bruno A. Natural killer cells in the orchestration of chronic inflammatory diseases. Journal of Immunology Research, 2017, 2017, 4218254. DOI: 10.1155/2017/4218254
[57]Yang Y, Day J, Souza-Fonseca Guimaraes F, Wicks IP, Louis C. Natural killer cells in inflammatory autoimmune diseases. Clinical & Translational Immunology, 2021, 10(2), e1250. DOI: 10.1002/cti2.1250
[58]Kucuksezer UC, Aktas Cetin E, Esen F, Tahrali I, Akdeniz N, Gelmez MY, et al. The role of natural killer cells in autoimmune diseases. Frontiers in Immunology, 2021, 12, 622306. DOI: 10.3389/fimmu.2021.622306
[59]Vandenhaute J, Wouters CH, Matthys P. Natural killer cells in systemic autoinflammatory diseases: A focus on systemic juvenile idiopathic arthritis and macrophage activation syndrome. Frontiers in Immunology, 2020, 10, 3089. DOI: 10.3389/fimmu.2019.03089
[60]Ness S, Lin S, Gordon JR. Regulatory dendritic cells, T cell tolerance, and dendritic cell therapy for immunologic disease. Frontiers in Immunology, 2021, 12, 633436. DOI: 10.3389/fimmu.2021.633436
[61]Álvarez-Carrasco P, Maldonado-Bernal C. The innate defenders: A review of natural killer cell immunotherapies in cancer. Frontiers in Immunology, 2024, 15, 1482807. DOI: 10.3389/fimmu.2024.1482807
[62]Jacobs B, Gebel V, Heger L, Grèze V, Schild H, Dudziak D, et al. Characterization and manipulation of the crosstalk between dendritic and natural killer cells within the tumor microenvironment. Frontiers in Immunology, 2021, 12, 670540. DOI: 10.3389/fimmu.2021.670540
[63]Gao J, Li M, Sun M, Yu Y, Kong R, Xu X, et al. Efficacy and safety of allogeneic CD19 CAR NK cell therapy in systemic lupus erythematosus: A case series in China. Lancet, 2026, 406(10522), 2968-2979. DOI: 10.1016/S0140-6736(25)01671-X
[64]Rodriguez MA, Blasini AM. Just autoimmunity? The role of the innate immune response in lupus. Journal of Clinical Rheumatology, 2025, 31(2), 71-77. DOI: 10.1097/RHU.0000000000002209
[65]Chanvillard C, Jacolik RF, Infante-Duarte C, Nayak RC. The role of natural killer cells in multiple sclerosis and their therapeutic implications. Frontiers in Immunology, 2013, 4, 63. DOI: 10.3389/fimmu.2013.00063
[66]Rodríguez-Morales P, Franklin RA. Macrophage phenotypes and functions: Resolving inflammation and restoring homeostasis. Trends in Immunology, 2023, 44(12), 986-998. DOI: 10.1016/j.it.2023.10.004
[67]Bödder J, Zahan T, van Slooten R, Schreibelt G, de Vries IJM, Flórez-Grau G. Harnessing the cDC1-NK cross-talk in the tumor microenvironment to battle cancer. Frontiers in Immunology, 2021, 11, 631713. DOI: 10.3389/fimmu.2020.631713
[68]Böttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends in Cancer, 2018, 4(11), 784-792. DOI: 10.1016/j.trecan.2018.09.001
[69]Maiorino L, Daßler-Plenker J, Sun L, Egeblad M. Innate immunity and cancer pathophysiology. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 425-457. DOI: 10.1146/annurev-pathmechdis-032221-115501
[70]Plesca I, Müller L, Böttcher JP, Medyouf H, Wehner R, Schmitz M. Tumor-associated human dendritic cell subsets: Phenotype, functional orientation, and clinical relevance. European Journal of Immunology, 2022, 52(11), 1750-1758. DOI: 10.1002/eji.202149487
[71]Björkström NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nature Reviews Immunology, 2022, 22(2), 112-123. DOI: 10.1038/s41577-021-00558-3
[72]Bjorgen JC, Dick JK, Cromarty R, Hart GT, Rhein J. NK cell subsets and dysfunction during viral infection: A new avenue for therapeutics? Frontiers in Immunology, 2023, 14, 1267774. DOI: 10.3389/fimmu.2023.1267774
[73]Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proceedings of the National Academy of Sciences, 2012, 109(4), 1210-1215. DOI: 10.1073/pnas.1118834109
[74]Arish M, Qian W, Narasimhan H, Sun J. COVID-19 immunopathology: From acute diseases to chronic sequelae. Journal of Medical Virology, 2023, 95(1), e28122. DOI: 10.1002/jmv.28122
[75]Vu SH, Pham HH, Pham TTP, Le TT, Vo MC, Jung SH, et al. Adoptive NK cell therapy-a beacon of hope in multiple myeloma treatment. Frontiers in Oncology, 2023, 13, 1275076. DOI: 10.3389/fonc.2023.1275076
[76]Cai M, Huang X, Huang X, Ju D, Zhu YZ, Ye L. Research progress of interleukin-15 in cancer immunotherapy. Frontiers in Pharmacology, 2023, 14, 1184703. DOI: 10.3389/fphar.2023.1184703
[77]Li J, Xiao C, Li C, He J. Tissue-resident immune cells: From defining characteristics to roles in diseases. Signal Transduction and Targeted Therapy, 2025, 10(1), 12. DOI: 10.1038/s41392-024-02050-5
[78]Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A. Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment: Recent advances and future prospects. Stem Cell Reviews and Reports, 2021, 17(6), 2081-2106. DOI: 10.1007/s12015-021-10246-3
[79]Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology, 2024, 21(10), 1089-1108. DOI: 10.1038/s41423-024-01207-0
[80]Marofi F, Rahman HS, Thangavelu L, Dorofeev A, Bayas-Morejón F, Shirafkan N, et al. The Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Research & Therapy, 2021, 12(1), 200. DOI: 10.1186/s13287-021-02251-7
[81]Ma S, Yu J, Caligiuri MA. Natural killer cell-based immunotherapy for cancer. The Journal of Immunology, 2025, 214(7), 1444-1456. DOI: 10.1093/jimmun/vkaf036
[82]Terrén I, Orrantia A, Astarloa-Pando G, Amarilla-Irusta A, Zenarruzabeitia O, Borrego F. Cytokine-induced memory-like NK cells: From the basics to clinical applications. Frontiers in Immunology, 2022, 13, 884648. DOI: 10.3389/fimmu.2022.884648
[83]Wang X, Zhao XY. Transcription factors associated with IL-15 cytokine signaling during NK cell development. Frontiers in Immunology, 2021, 12, 610789. DOI: 10.3389/fimmu.2021.610789
[84]Zhi L, Wang Y, Zhao Z, Guo Y, Wang K, He W, et al. Mechanisms and strategies for reversing NK cell exhaustion in tumor immunotherapy. Experimental and Molecular Pathology, 2026, 145, 105031. DOI: 10.1016/j.yexmp.2026.105031
[85]van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, et al. Monalizumab: Inhibiting the novel immune checkpoint NKG2A. Journal for Immunotherapy of Cancer, 2019, 7(1), 263. DOI: 10.1186/s40425-019-0761-3
[86]Blunt MD, Khakoo SI. Harnessing natural killer cell effector function against cancer. Immunotherapy Advances, 2023, 4(1), ltad031. DOI: 10.1093/immadv/ltad031
[87]Mehrani Y, Morovati S, Keivan F, Sarmadi S, Shojaei S, Forouzanpour D, et al. Dendritic cell-based cancer vaccines: The impact of modulating innate lymphoid cells on anti-tumor efficacy. Cells, 2025, 14(11), 812. DOI: 10.3390/cells14110812
[88]Pastor Y, Ghazzaui N, Hammoudi A, Centlivre M, Cardinaud S, Levy Y. Refining the DC-targeting vaccination for preventing emerging infectious diseases. Frontiers in Immunology, 2022, 13, 949779. DOI: 10.3389/fimmu.2022. 949779
[89]Wang Z, Yang X, Li J, Chen G, Ma H, Xu Z, et al. Development of a dendritic cell-targeted vaccine strategy using proximity-induced conjugation. Theranostics, 2026, 16(9), 4641-4656. DOI: 10.7150/thno.122332
[90]Zanotta S, Galati D, De Filippi R, Pinto A. Enhancing dendritic cell cancer vaccination: The synergy of immune checkpoint inhibitors in combined therapies. International Journal of Molecular Sciences, 2024, 25(14), 7509. DOI: 10.3390/ijms25147509
[91]Passeri L, Marta F, Bassi V, Gregori S. Tolerogenic dendritic cell-based approaches in autoimmunity. International Journal of Molecular Sciences, 2021, 22(16), 8415. DOI: 10.3390/ijms22168415
[92]Barran G, Naamane N, Baru AM, Anderson AE, Falconer J, Hilkens CMU. Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4+ T cells. Frontiers in Immunology, 2025, 16, 1698413. DOI: 10.3389/fimmu.2025.1698413
[93]Long EL, Stanway J, White M, Goudie N, Phillipson J, Morton M, et al. Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2 (AuToDeCRA-2) study: Protocol for a single-center, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for rheumatoid arthritis. Trials, 2025, 26(1), 278. DOI: 10.1186/s13063-025-08972-x
[94]Bar-On L, Cohen H, Elia U, Cherry-Mimran L, Cohen O, Erez N. The mRNA component of LNP-mRNA vaccines triggers IFNAR-dependent immune activation, which attenuates the adaptive immune response. Frontiers in Immunology, 2025, 16, 1670350. DOI: 10.3389/fimmu.2025.1670350
[95]Cianga VA, Antohe I, Minciună C, Dăscălescu A. Engineering immunity with CAR-NK cells: Advancing the frontiers of cancer immunotherapy. Frontiers in Pharmacology, 2025, 16, 1738558. DOI: 10.3389/fphar.2025.1738558
[96]Mitra A, Kumar A, Amdare NP, Pathak R. Current landscape of cancer immunotherapy: Harnessing the immune arsenal to overcome immune evasion. Biology, 2024, 13(5), 307. DOI: 10.3390/biology13050307
[97]Huang Y, Liao H, Luo J, Wei H, Li A, Lu Y, et al. Reversing NK cell exhaustion: A novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma. Frontiers in Oncology, 2025, 14, 1502270. DOI: 10.3389/fonc.2024.1502270
[98]Alharthi R, Mehmood R, Albeshri A. A Systematic, Scalable, and Interpretable Mapping of Artificial Intelligence Research in Leukemia Using a Hybrid Machine Learning and Qualitative Framework. Electronics, 2026, 15(5), 1078. DOI: 10.3390/electronics15051078
[99]Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, et al. Tissue determinants of human NK cell development, function, and residence. Cell, 2020, 180(4), 749-763. e13. DOI: 10.1016/j.cell.2020.01.022
[100]Liang C, Yue M, Zhang K, Zhou S, Xu X, Wang S, et al. Defining the role of natural killer cells in acute myeloid leukemia through the lens of single-cell omics. Frontiers in Immunology, 2026, 17, 1734327. DOI: 10.3389/fimmu.2026.1734327
[101]Rebuffet L, Melsen JE, Escalière B, Basurto-Lozada D, Bhandoola A, Björkström NK, et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nature Immunology, 2024, 25(8), 1474-1488. DOI: 10.1038/s41590-024-01883-0
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Abdelrahman Hemdan, Nagla Usama, Omneya Abdelkarem (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.